What Keeps Michael Bishop, MD, Up at Night When it Comes to CAR-T?

By Chadi Nabhan, MD, MBA, FACP - Last Updated: August 1, 2023

What is it about chimeric antigen receptor (CAR) T-cell therapies in hematologic oncology that keeps Michael Bishop, MD, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago, awake at night? In the latest episode of the podcast, Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about research that is identifying why CAR T-cell therapy doesn’t always work.

Advertisement
Advertisement
Advertisement
Editorial Board